A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

被引：0

作者：

Park, Byeong-Bae ^{[1
]}

Kim, Won Seog ^{[2
]}

Suh, Cheolwon ^{[3
]}

Yoon, Dok Hyun ^{[3
]}

Won, Jong-Ho ^{[4
]}

Yang, Deok-Hwan ^{[5
]}

Do, Young-Rok ^{[6
]}

Lee, Won Sik ^{[7
]}

Kim, Jeong-A ^{[8
]}

Kim, Min Kyoung ^{[9
]}

Jo, Jae-Cheol ^{[10
]}

Koh, Youngil ^{[11
]}

机构：

[1] Hanyang Univ, Coll Med, Seoul, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[4] Soonchunhyang Univ, Coll Med, Seoul, South Korea

[5] Chonnam Natl Univ Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea

[6] Dongsan Med Ctr, Daegu, South Korea

[7] Inje Univ, Coll Med, Busan, South Korea

[8] Catholic Univ Korea, St Vincents Hosp, Suwon, South Korea

[9] Yeungnam Univ Med Ctr, Daegu, South Korea

[10] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea

[11] Seoul Natl Univ Hosp, Seoul, South Korea

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1823.1823

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1823

引用

页数：5

共 50 条

[1] A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
Park, Byeong-Bae
Kim, Won Seog
Suh, Cheolwon
Hong, Jung Yong
Yang, Deok-Hwan
Lee, Won Sik
Do, Young Rok
Koh, Young Il
Won, Jong-Ho
Kim, Min Kyoung
Jo, Jae-Cheol
Hyun, Shin Young
Kim, Jeong-A
Oh, Young Ha
Lee, Seung-Sook
LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3251 - 3257
[2] Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
Park, Byeong-Bae
Kim, Won Seog
Suh, Cheolwon
Shin, Dong-Yeop
Kim, Jeong-A
Kim, Hoon-Gu
Lee, Won Sik
ANNALS OF HEMATOLOGY, 2015, 94 (11) : 1845 - 1851
[3] Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
Byeong-Bae Park
Won Seog Kim
Cheolwon Suh
Dong-Yeop Shin
Jeong-A Kim
Hoon-Gu Kim
Won Sik Lee
Annals of Hematology, 2015, 94 : 1845 - 1851
[4] Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.
Gressin, Remy
Damaj, Gandhi Laurent
Bouabdallah, Kamal
Cartron, Guillaume
Choufi, B.
Gyan, Emmanuel
Jaccard, Arnaud
Park, Sophie
De Colella, Jean-Marc Schiano
Voillat, Laurent
Joly, Bertrand
Le Gouill, Steven
Saad, Alain
Sanhes, Laurence
Moles-Moreau, Marie-Pierre
Bubenheim, Michael
Bene, Marie C.
Martin, Antoine
Marolleau, Jean Pierre
Lamy, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
Krishnan, Mridula
Bociek, R. Gregory
Fanale, Michelle
Iyer, Swaminathan P.
Lechowicz, Mary Jo
Bierman, Philip J.
Armitage, James O.
Lunning, Matthew
Kallam, Avyakta
Vose, Julie M.
ANNALS OF HEMATOLOGY, 2022, 101 (02) : 335 - 340
[6] Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma
Mridula Krishnan
R. Gregory Bociek
Michelle Fanale
Swaminathan P. Iyer
Mary Jo Lechowicz
Philip J. Bierman
James O. Armitage
Matthew Lunning
Avyakta Kallam
Julie M. Vose
Annals of Hematology, 2022, 101 : 335 - 340
[7] A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Oh, Sung Yong
Kim, Won Seog
Kim, Jin Seok
Chae, Yee Soo
Lee, Gyeong-Won
Eom, Hyeon Seok
Ryoo, Hun Mo
Lee, Suee
Kim, Seok Jin
Yoon, Dok Hyun
Won, Jong Ho
Hong, Junshik
Park, Jinny
Lee, Sang-Min
Hong, Jung Yong
Park, Eunkyung
Kim, Hyo Jung
Yang, Deok-Hwan
Kim, Hyo-Jin
Suh, Cheolwon
LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1406 - 1412
[8] UPDATED RESULTS OF A PHASE II TRIAL OF BENDAMUSTINE IN RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
Moskowitz, A. J.
Hamlin, P.
Gerecitano, J.
Horwitz, S.
Matasar, M.
Noy, A.
Palomba, M. L.
Portlock, C.
Straus, D.
Graustein, T.
Zelenetz, A.
Moskowitz, C.
ANNALS OF ONCOLOGY, 2011, 22 : 180 - 181
[9] Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig, Thomas
Sokol, Lubomir
Kim, Won Seog
Vicente, Fatima de la Cruz
Garcia-Sancho, Alejandro Martin
Advani, Ranjana
Vidal, Jose Maria Roncero
Navarrete, Raquel de Ona
Marin-Niebla, Ana
Izquierdo, Antonia Rodriguez
Terol, Maria Jose
Domingo-Domenech, Eva
Saunders, Andrew
Bendris, Nawal
Mackey, Julie
Leoni, Mollie
Foss, Francine
BLOOD ADVANCES, 2024, 8 (17) : 4581 - 4592
[10] Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
Piekarz, R
Frye, R
Turner, M
Wright, J
Leonard, J
Allen, S
Bates, S
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 202S - 202S

← 1 2 3 4 5 →